MET Inhibitor Shows Antitumor Activity in Advanced NSCLC
Interim data from a phase 2 trial suggests that MET inhibitor tepotinib has antitumor activity and a tolerable safety profile in advanced MET exon 14 skipping mutated NSCLC.
|The following article features coverage from the International Association for the Study of Lung Cancer (IASLC) 2018 meeting. Click here to read more of Cancer Therapy Advisor's conference coverage.|
The MET inhibitor tepotinib showed antitumor activity with a tolerable safety profile in patients with advanced non-small cell lung cancer (NSCLC) that harbored the MET exon 14 skipping mutation (METex14), according to interim phase 2 data presented at the IASLC's 19th World Conference on Lung Cancer in Toronto, Canada.1
Approximately 3% of patients with NSCLC harbor METex14. The aim of this trial was to determine the efficacy and safety of a MET inhibitor that targets this mutation.
The ongoing phase 2 trial is recruiting approximately 120 patients with advanced NSCLC with METex14, but without EGFR-activating mutations or ALK rearrangements, for treatment with 500 mg of tepotinib daily until disease progression, intolerable toxicity, or withdrawal. The primary end point is objective response rate, and the secondary end point is safety.
Of the planned recruitment, 41 patients have received treatment. Of the 34 patients with available data, the median patient age was 73.5, 68% were male, and most received 0 to 2 prior lines of therapy.
Of the 22 patients evaluable for efficacy, 59.1% (13 patients) demonstrated a response, including 1 complete response, 12 partial response, and 3 with stable disease, according to investigator assessment. Independent assessment found that 9 patients had a partial response and 5 patients demonstrated stable disease.
The duration of response was more than 12 months for 2 patients, and treatment is ongoing in 24 patients.
Treatment-related, treatment-emergent adverse events (TRTEAEs) occurred in 58.8% of patients; 8.8% experienced serious events that included pneumonia, generalized edema, and interstitial lung disease. Grade 3 TRTEAEs occurred in 17.6% of patients and, in addition to these serious events, included elevated liver function enzymes and hyperkalemia. There were no treatment-related deaths.
The investigators concluded that these results suggest that tepotinib has promising antitumor activity in this population, and has a favorable safety profile as well.
Read more of Cancer Therapy Advisor's coverage of the IASLC 2018 meeting by visiting the conference page.
- Felip E, Sakai H, Patel J, et al. Phase 2 data for the met inhibitor tepotinib in patients with advanced NSCLC and MET exon 14-skipping mutations. Presented at: International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer; Toronto, Canada; September 23-26, 2018. Abstract OA12.01.